INCHEON, South Korea and JERSEY CITY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the U.S. Food and Drug Administration (FDA) ...
The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...
Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 ml, 40 mg/0.8 ml) autoinjectors and ...
Autoinjector recognized by the Arthritis Foundation with Ease of Use Certification Individualized patient support program “HADLIMA For You” available including co-pay support Designed to improve ...
Share on Pinterest Humira will soon have a citrate-free biosimilar available on the market. Humira (adalimumab) is a popular medication used to treat various inflammatory conditions including ...
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...
In the last week, seven adalimumab biosimilars referencing HUMIRA entered the U.S. market: Boehringer Ingelheim’s CYLTEZO (adalimumab-adbm); Sandoz’s HYRIMOZ (adalimumab-adaz); Organon and Samsung ...
As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...
(Reuters) - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s blockbuster arthritis drug Humira, while two other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results